HIV-Seq Tool Finds Active Reservoir Cells During Therapy

Why It Matters

It proves that HIV reservoirs remain transcriptionally active under ART, reshaping cure strategies and informing risk assessments for viral rebound.

Key Takeaways

• HIV‑seq captures thousands of active reservoir cells, far beyond standard methods
• Treated patients' reservoir cells show anti‑inflammatory, pro‑survival gene signatures
• Untreated patients' cells display cytotoxic, inflammatory profiles
• Active viral RNA persists despite suppressive antiretroviral therapy
• Tool reveals potential drug targets to block reservoir cell survival

Pulse Analysis

The persistence of a latent HIV reservoir remains the chief obstacle to a functional cure. While antiretroviral therapy (ART) suppresses plasma viremia, low‑level viral transcription continues in a subset of infected CD4⁺ T cells, fueling chronic inflammation and the risk of rapid rebound if treatment lapses. Traditional single‑cell RNA sequencing has struggled to detect these cells because HIV‑derived transcripts often lack the poly‑A tails required for capture, yielding only one or two cells per patient and limiting biological insight.

The newly introduced HIV‑seq platform overcomes this limitation by employing virus‑specific capture primers that enrich HIV RNA during library preparation. In head‑to‑head comparisons, the method recovered 25 reservoir cells from three ART‑suppressed individuals and more than 1,000 cells from untreated donors—orders of magnitude higher than conventional approaches. Molecular profiling revealed a stark phenotypic shift: pre‑therapy cells exhibited cytotoxic, inflammatory signatures, whereas cells persisting under ART displayed anti‑inflammatory, pro‑survival gene programs, including up‑regulated pathways that protect against apoptosis.

These insights reshape our understanding of the reservoir as a dynamic, metabolically active population rather than a dormant dump. By pinpointing survival pathways and surface proteins unique to ART‑resistant cells, HIV‑seq opens a pipeline for targeted interventions—such as small‑molecule inhibitors or immunotherapies—that could selectively purge the active reservoir. The tool also offers a scalable assay for clinical trials, enabling precise monitoring of reservoir dynamics and accelerating the evaluation of cure‑focused strategies across the biotech and pharmaceutical sectors.